Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Current Assets (2016 - 2025)

Historic Current Assets for BioRestorative Therapies (BRTX) over the last 15 years, with Q3 2025 value amounting to $4.7 million.

  • BioRestorative Therapies' Current Assets fell 6515.3% to $4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.7 million, marking a year-over-year decrease of 6515.3%. This contributed to the annual value of $11.1 million for FY2024, which is 216.24% down from last year.
  • According to the latest figures from Q3 2025, BioRestorative Therapies' Current Assets is $4.7 million, which was down 6515.3% from $7.6 million recorded in Q2 2025.
  • In the past 5 years, BioRestorative Therapies' Current Assets ranged from a high of $21.5 million in Q4 2021 and a low of $1.2 million during Q3 2021
  • For the 5-year period, BioRestorative Therapies' Current Assets averaged around $11.4 million, with its median value being $12.3 million (2023).
  • In the last 5 years, BioRestorative Therapies' Current Assets skyrocketed by 479492.84% in 2021 and then crashed by 6515.3% in 2025.
  • BioRestorative Therapies' Current Assets (Quarter) stood at $21.5 million in 2021, then decreased by 29.53% to $15.1 million in 2022, then dropped by 24.71% to $11.4 million in 2023, then decreased by 2.16% to $11.1 million in 2024, then crashed by 57.76% to $4.7 million in 2025.
  • Its Current Assets stands at $4.7 million for Q3 2025, versus $7.6 million for Q2 2025 and $9.4 million for Q1 2025.